<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606758</url>
  </required_header>
  <id_info>
    <org_study_id>8</org_study_id>
    <nct_id>NCT04606758</nct_id>
  </id_info>
  <brief_title>Fluoroscopic Guided vs US-guided Percutaneous Nephrolithotripsy for the Treatment of Stone Disease</brief_title>
  <official_title>Randomized Controlled Trial Comparing Surgical Outcomes Following PCNL Under Ultrasound Control and PCNL Under Fluoroscopic Control in the Treatment of Kidney Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astana Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medipol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Astana Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized comparison of patient outcomes following fluoroscopic guided PCNL versus&#xD;
      ultrasound-guided PCNL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled trial that compares the operative outcomes and&#xD;
      complications of fluoroscopic guided-percutaneous nephrolithotomy versus ultrasound-guided&#xD;
      PCNL for renal stones. This study will be a prospective randomized controlled clinical trial&#xD;
      with patients who have already agreed to undergo PCNL. Patients will be randomized at a 1:1&#xD;
      ratio to receive either PCNL under fluoroscopic guidance or PCNL under ultrasound guidance.&#xD;
      Patients will be asked to complete pre-operative, and postoperative quality of life&#xD;
      questionnaires, and to allow the collection of one additional vial of blood for measurement&#xD;
      of factors associated with inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss as estimated by postoperative decreases in haemoglobin</measure>
    <time_frame>Post-operative day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Outcome measures by using the clavien dindo classification system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asses the easiness of accessibility of the targeted stone</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Outcome measures by counting numbers of puncture trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Puncture fluoroscopy screening time</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>assessed on the monitor of C-Arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Urolithiasis</condition>
  <condition>Kidney Stone</condition>
  <condition>Kidney Diseases</condition>
  <condition>Ureteral Calculi</condition>
  <condition>Kidney Calculi</condition>
  <arm_group>
    <arm_group_label>PCNL under fluoroscopic control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PCNL under ultrasound control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCNL under fluoroscopic control</intervention_name>
    <description>Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance</description>
    <arm_group_label>PCNL under fluoroscopic control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCNL under ultrasound control</intervention_name>
    <description>Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance</description>
    <arm_group_label>PCNL under ultrasound control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients planned for PCNL at participating institution&#xD;
&#xD;
          -  Patients of all ethnic backgrounds&#xD;
&#xD;
          -  Stone size over 10 mm in diameter and a density over 900 Hounsfield units&#xD;
&#xD;
          -  Patients with a large calculus in the upper third of the ureter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  infectious disease of the genitals;&#xD;
&#xD;
          -  conditions that violate the configuration of the kidneys (curvature of the spinal&#xD;
             column)&#xD;
&#xD;
          -  anomalies in the development of the kidneys with impaired configuration and position&#xD;
             of the kidneys (horseshoe kidney, bisque kidney, S-shaped kidney, L-shaped kidney,&#xD;
             lumbar dystopia, iliac dystopia, pelvic dystopia)&#xD;
&#xD;
          -  presence of nephrostomy drainage in the target kidney;&#xD;
&#xD;
          -  urethral stricture or other reason leading to the inability to carry out ureteral&#xD;
             catheterization;&#xD;
&#xD;
          -  other conditions that are contraindications to surgical treatment, such as&#xD;
             uncontrolled diabetes mellitus, acute cardiovascular conditions, liver failure,&#xD;
             alcoholism, and drug addiction;&#xD;
&#xD;
          -  patients who are unable to understand the purpose of the study or refuse further&#xD;
             follow-up observation and instructions after treatment;&#xD;
&#xD;
          -  patients with a history of mental illness;&#xD;
&#xD;
          -  participation in another research that interferes with this research;&#xD;
&#xD;
          -  acute renal failure;&#xD;
&#xD;
          -  dissecting aortic aneurysm;&#xD;
&#xD;
          -  acute hypertensive encephalopathy;&#xD;
&#xD;
          -  heavy arterial bleeding;&#xD;
&#xD;
          -  myocardial infarction less than six months before enrollment in the study;&#xD;
&#xD;
          -  Stroke less than six months before enrollment in the study;&#xD;
&#xD;
          -  Insufficiency of blood circulation III-IV New York Heart Association class;&#xD;
&#xD;
          -  Severe rhythm and conduction disturbances;&#xD;
&#xD;
          -  Increase in the level of liver transaminases by more than three times;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ulanbek Zhanbyrbekuly</last_name>
    <phone>+77071652019</phone>
    <email>ulanbek.amu@gmail.com</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

